Polaryx Therapeutics receives both rare paediatric disease and orphan drug designations for the treatment of GM2 gangliosidosis with PLX-300

25 November 2020 - Polaryx Therapeutics announced today that it has received from the U.S. FDA both rare paediatric disease and ...

Read more →

FDA approves first treatment for weight management for people with certain rare genetic conditions

27 November 2020 - The U.S. FDA has approved Imcivree (setmelanotide) for chronic weight management (weight loss and weight maintenance for ...

Read more →

Protalix BioTherapeutics and Chiesi Global Rare Diseases announce extension of PDUFA date for pegunigalsidase alfa for the proposed treatment of Fabry disease

27 November 2020 - Protalix BioTherapeutics today announced that the U.S. FDA has extended the Prescription Drug User Fee Act (PDUFA) ...

Read more →

Global regulators urge continuation of COVID-19 vaccine trials for longer-term safety and efficacy follow-up

27 November 2020 - EMA has endorsed a statement by the International Coalition of Medicines Regulatory Authorities that urges all stakeholders, ...

Read more →

TGA announces approval of new medicine from ASX listed company

26 November 2020 - Afamelanotide acetate (Scenesse) was approved on 22 October 2020. ...

Read more →

After admitting mistake, AstraZeneca faces difficult questions about its vaccine

25 November 2020 - Some trial participants only got a partial dose of AstraZeneca’s vaccine. Experts said the company’s spotty disclosures ...

Read more →

European Medicines Agency validates application for tepotinib for the treatment of advanced NSCLC with METex14 skipping alterations

26 November 2020 - Merck today announced that the EMA has validated for review, the application for tepotinib for the ...

Read more →

Moderna signs deal with EU for 160 million COVID-19 vaccine doses

26 November 2020 - The European Commission has signed a supply deal with Moderna which will see it secure an ...

Read more →

FDA defers approval of daxibotulinumtoxinA for injection in glabellar lines due to COVID-19 related travel restrictions impacting manufacturing site inspection

25 November 2020 - Revance Therapeutics today announced that the United States FDA has deferred a decision on the biologics license ...

Read more →

European Commission approves Janssen’s Tremfya (guselkumab), a first-in-class treatment for active psoriatic arthritis

25 November 2020 - Guselkumab is the first selective IL-23 p19 subunit inhibitor licensed for both the treatment of psoriatic arthritis ...

Read more →

Bio-Thera Solutions submits marketing authorisation application for BAT1706, a proposed biosimilar to Avastin, to European Medicines Agency

25 November 2020 - Bio-Thera Solutions today announced that it has submitted the marketing authorisation application for BAT1706, a proposed biosimilar ...

Read more →

Lynparza (olaparib) receives Health Canada approval for the treatment of BRCA or ATM gene-mutated metastatic castration-resistant prostate cancer

25 November 2020 - On 21 August 2020, Health Canada approved Lynparza (olaparib), for the treatment of adult patients with deleterious ...

Read more →

FDA grants accelerated approval to naxitamab for high-risk neuroblastoma in bone or bone marrow

25 November 2020 - On 24 November 2020, the FDA granted accelerated approval to naxitamab (Danyelza, Y-mAbs Therapeutics) in combination with ...

Read more →

RhoVac's prostate cancer drug candidate RV001 is granted fast track designation by the FDA

25 November 2020 - RhoVac, a clinical stage company today announced that the American FDA has granted Fast Track Designation to ...

Read more →

AstraZeneca gears up to vaccinate the world against COVID-19

24 November 2020 - Among the front-runners racing to deliver a COVID-19 shot, has the least vaccine experience. But it has ...

Read more →